{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:08:31Z","timestamp":1791054511346,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1053\/j.gastro.2012.02.015","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T04:10:21Z","timestamp":1335240621000},"page":"1340-1350.e1","source":"Crossref","is-referenced-by-count":73,"title":["Anti\u2212Hepatitis C Virus Drugs in Development"],"prefix":"10.1053","volume":"142","author":[{"given":"Esperance A.K.","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1053\/j.gastro.2012.02.015_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2011.01499.x","article-title":"The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference","volume":"18","author":"Hatzakis","year":"2011","journal-title":"* J Viral Hepat"},{"key":"10.1053\/j.gastro.2012.02.015_bib2","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/605947","article-title":"Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection","volume":"200","author":"Page","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib3","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1086\/522608","article-title":"Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance","volume":"196","author":"Wang","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib4","first-page":"562","article-title":"Long-term effects of antiviral therapy in patients with chronic hepatitis C","volume":"2010","author":"Kagawa","year":"2010","journal-title":"Hepat Res Treat"},{"key":"10.1053\/j.gastro.2012.02.015_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00535-005-1740-7","article-title":"Antiviral therapy for chronic hepatitis C: past, present, and future","volume":"41","author":"Hayashi","year":"2006","journal-title":"J Gastroenterol"},{"key":"10.1053\/j.gastro.2012.02.015_bib6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2012.02.015_bib7","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.0511218103","article-title":"Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro","volume":"103","author":"Lindenbach","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2012.02.015_bib8","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1074\/jbc.M110.175018","article-title":"Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome","volume":"286","author":"Merz","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2012.02.015_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.chom.2009.02.001","article-title":"A functional genomic screen identifies cellular cofactors of hepatitis C virus replication","volume":"5","author":"Tai","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1053\/j.gastro.2012.02.015_bib10","doi-asserted-by":"crossref","first-page":"15865","DOI":"10.1073\/pnas.2237238100","article-title":"Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation","volume":"100","author":"Ye","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2012.02.015_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tem.2011.03.004","article-title":"Unique ties between hepatitis C virus replication and intracellular lipids","volume":"22","author":"Herker","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1053\/j.gastro.2012.02.015_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"key":"10.1053\/j.gastro.2012.02.015_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1089-3261(02)00065-X","article-title":"Hepatitis C virus genetic variability: pathogenic and clinical implications","volume":"7","author":"Pawlotsky","year":"2003","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2012.02.015_bib15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib16","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.015_bib17","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.015_bib18","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.015_bib19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.015_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.015_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cir882","article-title":"Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons","author":"Thomas","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib23","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib24","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.gastro.2011.05.046","article-title":"Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections","volume":"141","author":"Foster","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","article-title":"Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3\/4A protease recombinant viruses","volume":"141","author":"Gottwein","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib28","series-title":"Presented as the American Association for the Study of Liver Diseases, Boston, MA","article-title":"Activity of telaprevir or in combination with peginterferon-alfa-2a and ribavirin the treatment-na\u00efve genotype 4 hepatitis-C patients: final results of Study C210","author":"Benhamou","year":"2010"},{"key":"10.1053\/j.gastro.2012.02.015_bib29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2011.05.014","article-title":"Second-wave protease inhibitors: choosing an heir","volume":"15","author":"Ciesek","year":"2011","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2012.02.015_bib31","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1128\/AAC.01058-08","article-title":"In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor","volume":"53","author":"Lin","year":"2009","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1053\/j.gastro.2012.02.015_bib32","series-title":"Presented as the American Association for the Study of Liver Diseases, Boston, MA","article-title":"Efficacy and safety of TMC435 in combination with PEG-interferon alpha-2A and ribavirin in treatment naive genotype 1 HCV patients: 24 week interim results from the PILLAR trial","author":"Fried","year":"2010"},{"key":"10.1053\/j.gastro.2012.02.015_bib33","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIb study","author":"Fried","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib34","first-page":"871","article-title":"TMC-435, an NS3\/4A protease inhibitor for the treatment of HCV infection","volume":"10","author":"Tsantrizos","year":"2009","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1053\/j.gastro.2012.02.015_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/jir315","article-title":"Antiviral activity of danoprevir (ITMN-191\/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C","volume":"204","author":"Forestier","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2011.01.046","article-title":"Antiviral activity, safety, and pharmacokinetics of danoprevir\/ritonavir plus PEG-IFN alpha-2a\/RBV in hepatitis C patients","volume":"55","author":"Gane","year":"2011","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2012.02.015_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2012.02.015_bib39","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1053\/j.gastro.2011.08.051","article-title":"Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection","volume":"141","author":"Zeuzem","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib41","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2012.02.015_bib42","doi-asserted-by":"crossref","first-page":"39260","DOI":"10.1074\/jbc.M506407200","article-title":"Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase","volume":"280","author":"Kukolj","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2012.02.015_bib43","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/AAC.00444-08","article-title":"Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479","volume":"52","author":"Ali","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2012.02.015_bib44","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1074\/jbc.M708929200","article-title":"2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups","volume":"283","author":"Klumpp","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2012.02.015_bib45","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1128\/JVI.05639-11","article-title":"HCV nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA","volume":"85","author":"Lam","year":"2011","journal-title":"J Virol"},{"key":"10.1053\/j.gastro.2012.02.015_bib46","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1086\/656774","article-title":"RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV)","volume":"202","author":"Le Pogam","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib47","series-title":"Presented as the American Association for the Study of Liver Diseases, Boston, MA","article-title":"High rates of early viral reponse, promising safety profile and lack of resistance-related breakthrough in HCV GT 1\/4 patients treated with RG7128 plus PEGIFN Alfa-2a\/RBV: planned week 12 interim analysis from the PROPEL Study","author":"Jensen","year":"2010"},{"key":"10.1053\/j.gastro.2012.02.015_bib48","doi-asserted-by":"crossref","unstructured":"Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PegIFN\/RBV in a phase 2B trial: rapid virologic suppression in treatment-na\u00efve patients with HCV GT2\/GT3. Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 2011.","DOI":"10.1016\/S0168-8278(11)60063-9"},{"key":"10.1053\/j.gastro.2012.02.015_bib49","unstructured":"Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PegIFN\/RBV in a Phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2\/GT3."},{"key":"10.1053\/j.gastro.2012.02.015_bib50","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or 3","author":"Gane","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib51","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cld.2011.05.002","article-title":"An overview of emerging therapies for the treatment of chronic hepatitis C","volume":"15","author":"Ilyas","year":"2011","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib52","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/hep.22563","article-title":"Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection","volume":"48","author":"McGovern","year":"2008","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cld.2011.05.003","article-title":"The HCV NS5B nucleoside and non-nucleoside inhibitors","volume":"15","author":"Membreno","year":"2011","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib54","article-title":"Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2a and ribavirin in chronically infected HCV genotype 1 patients","author":"Jacobson","year":"2010","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Vienna, Austria, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib55","article-title":"A Phase 2b trial comparing 24 to 48 weeks of treatment with tegobuvir (GS-9190)\/PEG\/RV to 48 weeks treatment with PEG\/RBV for chronic genotype 1 HCV infection","author":"Lawitz","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib56","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","article-title":"Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052","volume":"85","author":"Fridell","year":"2011","journal-title":"J Virol"},{"key":"10.1053\/j.gastro.2012.02.015_bib57","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1099\/vir.0.022186-0","article-title":"Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes","volume":"91","author":"Ferraris","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1053\/j.gastro.2012.02.015_bib58","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1099\/vir.0.80204-0","article-title":"Hepatitis C virus NS5A: tales of a promiscuous protein","volume":"85","author":"Macdonald","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1053\/j.gastro.2012.02.015_bib59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jhep.2006.11.013","article-title":"HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines","volume":"46","author":"Lan","year":"2007","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2012.02.015_bib60","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.cld.2011.05.010","article-title":"The NS5A replication complex inhibitors: difference makers?","volume":"15","author":"Gish","year":"2011","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2012.02.015_bib62","doi-asserted-by":"crossref","unstructured":"Pol S, Ghalib RH, Rustgi VK, et al. First report of SVR12 for a NS5A replication complex inhibitor, BMS-790052 in combination with peg-IFN-alfa-2a and RBV: phase 2a trial in treatment-naive HCV-genotype 1 subjects. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011). Berlin. March 30\u2013April 3.","DOI":"10.1016\/S0168-8278(11)61375-5"},{"key":"10.1053\/j.gastro.2012.02.015_bib63","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib64","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib65","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% SVR12 in HCV genotype 1b-infected null reponders","author":"Chayama","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib66","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2012.02.015_bib67","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2012.02.015_bib68","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib69","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2012.02.015_bib70","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2012.02.015_bib71","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","article-title":"A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"139","author":"Tillmann","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1053\/j.gastro.2012.02.015_bib73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1053\/j.gastro.2012.02.015_bib74","doi-asserted-by":"crossref","first-page":"20869","DOI":"10.1074\/jbc.M109.002923","article-title":"Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family","volume":"284","author":"Gad","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2012.02.015_bib75","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2010.11.019","article-title":"IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway","volume":"55","author":"Zhang","year":"2011","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2012.02.015_bib76","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.21312","article-title":"Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes","volume":"44","author":"Doyle","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib77","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","article-title":"Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics","volume":"131","author":"Marcello","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib78","doi-asserted-by":"crossref","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Pathogens"},{"key":"10.1053\/j.gastro.2012.02.015_bib79","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib80","article-title":"Safety and efficacy of pegylated interferon lambda compared to pegylated interferon alfa 2a in HCV infected patients (G1\/2\/3) with compensated cirrhosis: EMERGE Phase IIB efficacy and safety results through week 12","author":"Rodriguez-Torres","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib81","first-page":"868","article-title":"Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus","volume":"20","author":"Teraoka","year":"1988","journal-title":"Transpl Proc"},{"key":"10.1053\/j.gastro.2012.02.015_bib82","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"Hanoulle","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2012.02.015_bib83","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2012.02.015_bib84","doi-asserted-by":"crossref","unstructured":"Hopkins S, Mosier S, Harris R, et al. Resistance selection following 15 days of monotherapy with SCY-635 a non-immunosuppressive cyclophilin inhibitor with potent anti-HCV activity. 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010). Vienna, Austria. April 14\u201318, 2010.","DOI":"10.1016\/S0168-8278(10)60036-0"},{"key":"10.1053\/j.gastro.2012.02.015_bib85","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"Coelmont","year":"2010","journal-title":"PloS One"},{"key":"10.1053\/j.gastro.2012.02.015_bib86","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22835","article-title":"The cyclophilin inhibitor Debio 025 combined with PEGIFN alpha2a significantly reduces viral load in treatment-naive hepatitis C patients","volume":"49","author":"Flisiak","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib87","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"Once daily alisporivir IFN-free regimens achieve high rates of early HCV clearance in previously untreated patients with genotype 2 or 3","author":"Pawlotsky","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib88","unstructured":"Flisiak R. Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April 3, 2011."},{"key":"10.1053\/j.gastro.2012.02.015_bib89","doi-asserted-by":"crossref","unstructured":"Flisiak R, Pawlotsky J-M, Crabb\u00e9 R, et al. Once daily alisporivir (DEB025) plus PegIFNalfa2a\/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011).","DOI":"10.1016\/S0168-8278(11)60006-8"},{"key":"10.1053\/j.gastro.2012.02.015_bib90","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"Alisporivir\u2014a host-targeting antiviral provides low viral breakthrough rate and high barrier to resistance in HCV genotype 1 treatment-naive patients in the Phase IIb ESSENTIAL study","author":"Li","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib91","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nature09267","article-title":"Mammalian microRNAs predominantly act to decrease target mRNA levels","volume":"466","author":"Guo","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2012.02.015_bib92","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2012.02.015_bib93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.chom.2008.05.013","article-title":"Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome","volume":"4","author":"Jopling","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1053\/j.gastro.2012.02.015_bib94","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1128\/JVI.00417-10","article-title":"Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122","volume":"84","author":"Jangra","year":"2010","journal-title":"J Virol"},{"key":"10.1053\/j.gastro.2012.02.015_bib95","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"A randomized, double-blind, placebo controlled safety and anti-viral proof of concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment naive patients with genotype 1 chronic HCV infection","author":"Janssen","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib96","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/infdis\/jir303","article-title":"Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase","volume":"204","author":"Peng","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.015_bib97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.21232","article-title":"Different anti-HCV profiles of statins and their potential for combination therapy with interferon","volume":"44","author":"Ikeda","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib98","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/hep.21554","article-title":"Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial","volume":"45","author":"O'Leary","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.015_bib99","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1572-0241.2008.01876.x","article-title":"Fluvastatin inhibits hepatitis C replication in humans","volume":"103","author":"Bader","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2012.02.015_bib100","article-title":"Potential enhancement of both early (EVR) and sustained (SVR) virological response by fluvastatin in chronic hepatitis C treated with standard pegIFN-ribavirin therapy","author":"Georgescu","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib101","article-title":"Quadruple therapy with BMS-790052, BMS-650032, and PEG-IFN\/RBV for 24 weeks results in 100% SVR12 in genotype 1 null responders","author":"Lok","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib102","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1053\/j.gastro.2011.10.020","article-title":"Interferon-free treatment regimens for hepatitis C: are we there yet?","volume":"141","author":"Sharma","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.015_bib103","series-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany","article-title":"SILENC-1: sustained virologic response (SVR) and safety of BI201335 combined with PEGInterferon alfa-2a and ribavirin (P\/R) in treatment naive patients with chronic genotype 1 HCV infection","author":"Sulkowski","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib104","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"Once daily narlaprevir and ritonavir in combination with peginterferon alfa-2b\/ribavirin for 12 weeks plus 12 weeks PR in treatment naive patients with HCV gentoype 1 (G1): SVR results from NEXT-1, a Phase 2 Study","author":"Vierling","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib105","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"High rapid virologic response (RVR) with ACH-1625 daily dosing plus PEGIFN-alpha 2a\/RBV in a 28 day Phase 2a trial","author":"Lalezari","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib106","article-title":"High sustained virological response (SVR) rate after danoprevir for only 14 days associated with PEG-interferon alfa-2a and ribavirin in treatment-naive chronic HCV genotype 1 patients","author":"Larrey","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib107","series-title":"Presented as the American Association for the Study of Liver Diseases, Boston, MA","article-title":"Sustained virologic response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C infection treated wtih Vaniprevir, a NS3\/4A protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","author":"Manns","year":"2010"},{"key":"10.1053\/j.gastro.2012.02.015_bib108","article-title":"ABT-450\/Ritonavir (ABT-450\/r) combined with pegylated interferon alpha-2a and ribavirin after 3-day monotherapy in genotype 1 HCV-infected treatment-na\u00efve subjects: 12-week interim efficacy and safety results","author":"Lawitz","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib109","article-title":"BMS-650032, an NS3 inhibitor, in combination with PEGinterferon alfa-2a and ribavirin in treatment naive subjects with genotype 1 chronic hepatitis C infection","author":"Bronowicki","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib110","article-title":"Four-week treatment with GS-9256 and tegobuvir (GS-9190) +\/- RBV +\/- PEG, results in enhanced viral suppression on follow-up PEG\/RBV therapy, in genotype 1a\/1b HCV patients","author":"Foster","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, March"},{"key":"10.1053\/j.gastro.2012.02.015_bib111","article-title":"MK-5172, a second generation HCV NS3\/4A protease inhibitor is active against common resistance associated variants (RAVs) and exhibits cross-genotype activity","author":"Graham","year":"2011","journal-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA"},{"key":"10.1053\/j.gastro.2012.02.015_bib112","article-title":"First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with PEG-inteferon\/ribavirin in treatment naive GT 1\/3 patients: interim analysis from the JUMP-C trial","author":"Pockros","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany"},{"key":"10.1053\/j.gastro.2012.02.015_bib113","series-title":"Presented at HepDart, Koloa, Hawaii","article-title":"PSI-7977 400mg with PEG\/RBV provides 93% SVR across GT 1, 2, and 3","author":"Lawitz","year":"2011"},{"key":"10.1053\/j.gastro.2012.02.015_bib115","article-title":"Factors affecting HCV viral load response to the non-nucleoside polymerase inhibitors ABT-072 and ABT-033","author":"Middleton","year":"2011","journal-title":"Presented at the European Association for the Study of the Liver, International Liver Conference, Berlin, Germany, April"},{"key":"10.1053\/j.gastro.2012.02.015_bib116","series-title":"Presented as the American Association for the Study of Liver Diseases, San Francisco, CA","article-title":"VX-222\/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive gentoype 1 HCV patients treated for 12 weeks: ZENITH study, SVR 12 interim analysis","author":"Nelson","year":"2011"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508512002284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508512002284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T15:48:25Z","timestamp":1561650505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508512002284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0016508512002284"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2012.02.015","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}